Tom Beausejour

Tom joined MedEquity Capital in 2016.
His primary responsibilities include sourcing and executing new platform investments, as well as working with portfolio company management teams to plan and execute on their respective growth strategies.
Tom also currently serves as a Director of Riverside Oral Surgery Management.
Prior to MedEquity, Tom worked in both corporate and advisory arenas, most recently at Vertex Pharmaceuticals, a Boston-based biotechnology firm which develops and commercializes novel drug therapies.
At Vertex, Tom managed all financial and valuation exercises used by senior leadership for optimal decisions on mergers and acquisitions, licensing and strategic initiatives.
Prior to Vertex, Tom was a valuation consultant at Duff & Phelps, now Kroll, where he managed client engagements for strategic, financial and tax purposes across a myriad of industries.
Tom has a degree in Finance from Boston College (Magna Cum Laude) and an MBA from the Harvard Business School.
He is also a Chartered Financial Analyst (CFA) and a member of the CFA Institute.
While not working, he enjoys spending time with his wife and young children, golfing and reading.